

NANOBAC PHARMACEUTICALS INC  
Form 15-12G  
May 20, 2011

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 15

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

NANOBAC PHARMACEUTICALS, INCORPORATED

(Exact name of registrant as specified in its charter)

Florida	033-80612	59-3248917
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification Number)

5025 West Lemon Street, Tampa, FL 33609

(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

Common

(Title of each class of securities covered by this Form)

None

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

- Rule 12g-4(a)(1)     x
- Rule 12g-4(a)(2)     o
- Rule 12h-3(b)(1)(i)  o
- Rule 12h-3(b)(1)(ii)  o
- Rule 15d-6             o

Approximate number of holders of record as of the certification or notice date: 238 shareholders

Pursuant to the requirements of the Securities Exchange Act of 1934, Nanobac Pharmaceuticals, Incorporated has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

NANOBAC PHARMACEUTICALS, INCORPORATED

Date: May 20, 2011

By: /s/ John Stanton  
John Stanton  
Chief Executive Officer & President